Professional
Added to YB: 2025-03-24
Pitch date: 2025-01-07
NVO [bullish]
Novo Nordisk A/S
-42.21%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 83.83
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Burke Wealth Management Portfolio Holding: Novo Nordisk A/S
NVO (holding update): Shares down on RFK Jr. HHS nomination & Cagri-Sema Phase III results (22.7% weight loss vs 25% target). Still in-line with Zepbound (20%) & better than Wegovy (15%). Obesity market potential huge, supply-constrained. Overreaction to results; Novo remains strong contender in growing GLP-1 market.
Read full article (2 min)